67. Vartak A, Sucheck S (2016) Recent advances
in subunit vaccine carriers. Vaccine 4(2):12
68. Zhang N, Zheng BJ, Lu L, Zhou Y, Jiang S,
Du L (2015) Advancements in the development of subunit influenza vaccines. Microbes
Infect 17(2):123–134. https://doi.org/10.
1016/j.micinf.2014.12.006
69. Astray RM, Jorge SA, Pereira CA (2017)
Rabies vaccine development by expression of
recombinant viral glycoprotein. Arch Virol
162(2):323–332. https://doi.org/10.1007/
s00705-016-3128-9
70. MacLennan CA, Martin LB, Micoli F (2014)
Vaccines against invasive Salmonella disease:
current status and future directions. Hum
Vaccin
Immunother
10(6):1478–1493.
https://doi.org/10.4161/hv.29054
71. Baliban SM, Yang M, Ramachandran G,
Curtis B, Shridhar S, Laufer RS et al (2017)
Development of a glycoconjugate vaccine to
prevent invasive Salmonella Typhimurium
infections in sub-Saharan Africa. PLoS Negl
Trop Dis 11(4):e0005493. https://doi.org/
10.1371/journal.pntd.0005493
72. Micoli F, Romano MR, Tontini M,
Cappelletti E, Gavini M, Proietti D,
Rondini S, Swennen E, Santini L, Filippini S,
Balocchi C (2013) Development of a glycoconjugate vaccine to prevent meningitis in
Africa caused by meningococcal serogroup
X. PNAS 110(47):19077–19082
73. Dertzbaugh MT (1998) Genetically engineered vaccines: an overview. Plasmid 39
(2):100–113
74. Gupta SK, Shukla P (2017) Gene editing for
cell engineering: trends and applications. Crit
Rev Biotechnol 37(5):672–684. https://doi.
org/10.1080/07388551.2016.1214557
75. Dangi AK, Sinha R, Dwivedi S, Gupta SK,
Shukla P (2018) Cell line techniques and
gene editing tools for antibody production: a
review. Front Pharmacol 9:630. https://doi.
org/10.3389/fphar.2018.00630
76. Nascimento IP, Leite LC (2012) Recombinant vaccines and the development of new
vaccine strategies. Braz J Med Biol Res 45
(12):1102–1111
77. Buck CB, Day PM, Trus BL (2013) The papillomavirus major capsid protein L1. Virology
445(1–2):169–174
78. Roland KL, Cloninger C, Kochi SK, Thomas
LJ, Tinge SA, Rouskey C, Killeen KP (2007)
Construction and preclinical evaluation of
recombinant Peru-15 expressing high levels
of the cholera toxin B subunit as a vaccine
against enterotoxigenic Escherichia coli. Vaccine 25(51):8574–8584
79. Gustavsson M, Do TH, Lu ¨thje P, Tran NT,
Brauner A, Samuelson P, Truong NH, Larsson G (2015) Improved cell surface display of
Salmonella enterica serovar Enteritidis antigens in Escherichia coli. Microb Cell Factories
14:47. https://doi.org/10.1186/s12934015-0227-3
80. Peng W, Liu S, Meng J, Huang J, Huang J,
Tang D, Dai Y (2019) Profiling the TRB and
IGH repertoire of patients with H5N6 Avian
Influenza Virus Infection by high-throughput
sequencing. Sci Rep 9(1):7429
81. Aunin ¸ s ˇ JG (2009) Viral vaccine production in
cell
culture.
In:
Flickinger
MC
(ed) Encyclopedia of industrial biotechnology: bioprocess, bioseparation, and cell technology. Wiley, New York, pp 1–35
82. Karch CP, Burkhard P (2016) Vaccine technologies: from whole organisms to rationally
designed protein assemblies. Biochem Pharmacol 120:1–14
83. WHO Expert Committee on Biological Standardization. WHO technical report series,
no. 941—Fifty-sixth report, Annex 6: recommendations for whole-cell pertussis vaccine,
301–33. WHO HQ, Geneva, 2007. http://
apps.who.int/medicinedocs/en/cl/CL7.
13/clmd,50.html
84. Chen Z, He Q (2017) Immune persistence
after pertussis vaccination. Hum Vaccin
Immunother 13(4):744–756
85. Xing D, Markey K, Das RG, Feavers I (2014)
Whole-cell pertussis vaccine potency assays:
the Kendrick test and alternative assays.
Expert Rev Vaccines 13(10):1175–1182.
https://doi.org/10.1586/14760584.2014.
939636
86. Corbel MJ, Xing DK (2004) Toxicity and
potency evaluation of pertussis vaccines.
Expert Rev Vaccines 3(1):89–101
87. Holmgren J, Levine MM (2015) Vaccines
against bacterial enteric infections. In:
Mestecky J, Strober W, Russel MW, Kelsall
BL, Cheroutre H, Lambrecht BN (eds)
Mucosal immunology, vol 1, 4th edn. Academic, New York, pp 1047–1082. https://
doi.org/10.1016/C2010-1-65194-2
88. Gustafsson L, Hallander HO, Olin P,
Reizenstein E, Storsaeter J (1995) A controlled trial of a two-component acellular, a
five-component acellular, and a whole-cell
pertussis vaccine. N Engl J Med 334
(6):349–356
89. Cabral MP, Garcı ´a P, Beceiro A, Rumbo C,
Pe ´rez A, Moscoso M, Bou G (2017) Design
of live attenuated bacterial vaccines based on
264
Punit Kumar et al.
in subunit vaccine carriers. Vaccine 4(2):12
68. Zhang N, Zheng BJ, Lu L, Zhou Y, Jiang S,
Du L (2015) Advancements in the development of subunit influenza vaccines. Microbes
Infect 17(2):123–134. https://doi.org/10.
1016/j.micinf.2014.12.006
69. Astray RM, Jorge SA, Pereira CA (2017)
Rabies vaccine development by expression of
recombinant viral glycoprotein. Arch Virol
162(2):323–332. https://doi.org/10.1007/
s00705-016-3128-9
70. MacLennan CA, Martin LB, Micoli F (2014)
Vaccines against invasive Salmonella disease:
current status and future directions. Hum
Vaccin
Immunother
10(6):1478–1493.
https://doi.org/10.4161/hv.29054
71. Baliban SM, Yang M, Ramachandran G,
Curtis B, Shridhar S, Laufer RS et al (2017)
Development of a glycoconjugate vaccine to
prevent invasive Salmonella Typhimurium
infections in sub-Saharan Africa. PLoS Negl
Trop Dis 11(4):e0005493. https://doi.org/
10.1371/journal.pntd.0005493
72. Micoli F, Romano MR, Tontini M,
Cappelletti E, Gavini M, Proietti D,
Rondini S, Swennen E, Santini L, Filippini S,
Balocchi C (2013) Development of a glycoconjugate vaccine to prevent meningitis in
Africa caused by meningococcal serogroup
X. PNAS 110(47):19077–19082
73. Dertzbaugh MT (1998) Genetically engineered vaccines: an overview. Plasmid 39
(2):100–113
74. Gupta SK, Shukla P (2017) Gene editing for
cell engineering: trends and applications. Crit
Rev Biotechnol 37(5):672–684. https://doi.
org/10.1080/07388551.2016.1214557
75. Dangi AK, Sinha R, Dwivedi S, Gupta SK,
Shukla P (2018) Cell line techniques and
gene editing tools for antibody production: a
review. Front Pharmacol 9:630. https://doi.
org/10.3389/fphar.2018.00630
76. Nascimento IP, Leite LC (2012) Recombinant vaccines and the development of new
vaccine strategies. Braz J Med Biol Res 45
(12):1102–1111
77. Buck CB, Day PM, Trus BL (2013) The papillomavirus major capsid protein L1. Virology
445(1–2):169–174
78. Roland KL, Cloninger C, Kochi SK, Thomas
LJ, Tinge SA, Rouskey C, Killeen KP (2007)
Construction and preclinical evaluation of
recombinant Peru-15 expressing high levels
of the cholera toxin B subunit as a vaccine
against enterotoxigenic Escherichia coli. Vaccine 25(51):8574–8584
79. Gustavsson M, Do TH, Lu ¨thje P, Tran NT,
Brauner A, Samuelson P, Truong NH, Larsson G (2015) Improved cell surface display of
Salmonella enterica serovar Enteritidis antigens in Escherichia coli. Microb Cell Factories
14:47. https://doi.org/10.1186/s12934015-0227-3
80. Peng W, Liu S, Meng J, Huang J, Huang J,
Tang D, Dai Y (2019) Profiling the TRB and
IGH repertoire of patients with H5N6 Avian
Influenza Virus Infection by high-throughput
sequencing. Sci Rep 9(1):7429
81. Aunin ¸ s ˇ JG (2009) Viral vaccine production in
cell
culture.
In:
Flickinger
MC
(ed) Encyclopedia of industrial biotechnology: bioprocess, bioseparation, and cell technology. Wiley, New York, pp 1–35
82. Karch CP, Burkhard P (2016) Vaccine technologies: from whole organisms to rationally
designed protein assemblies. Biochem Pharmacol 120:1–14
83. WHO Expert Committee on Biological Standardization. WHO technical report series,
no. 941—Fifty-sixth report, Annex 6: recommendations for whole-cell pertussis vaccine,
301–33. WHO HQ, Geneva, 2007. http://
apps.who.int/medicinedocs/en/cl/CL7.
13/clmd,50.html
84. Chen Z, He Q (2017) Immune persistence
after pertussis vaccination. Hum Vaccin
Immunother 13(4):744–756
85. Xing D, Markey K, Das RG, Feavers I (2014)
Whole-cell pertussis vaccine potency assays:
the Kendrick test and alternative assays.
Expert Rev Vaccines 13(10):1175–1182.
https://doi.org/10.1586/14760584.2014.
939636
86. Corbel MJ, Xing DK (2004) Toxicity and
potency evaluation of pertussis vaccines.
Expert Rev Vaccines 3(1):89–101
87. Holmgren J, Levine MM (2015) Vaccines
against bacterial enteric infections. In:
Mestecky J, Strober W, Russel MW, Kelsall
BL, Cheroutre H, Lambrecht BN (eds)
Mucosal immunology, vol 1, 4th edn. Academic, New York, pp 1047–1082. https://
doi.org/10.1016/C2010-1-65194-2
88. Gustafsson L, Hallander HO, Olin P,
Reizenstein E, Storsaeter J (1995) A controlled trial of a two-component acellular, a
five-component acellular, and a whole-cell
pertussis vaccine. N Engl J Med 334
(6):349–356
89. Cabral MP, Garcı ´a P, Beceiro A, Rumbo C,
Pe ´rez A, Moscoso M, Bou G (2017) Design
of live attenuated bacterial vaccines based on
264
Punit Kumar et al.